Serum anti-cholesterol antibodies in chronic hepatitis-C patients during IFN-α-2b treatment

Adrienn Bíró, A. Horváth, L. Varga, Elemér Nemesánszky, Antal Csepregi, Károly Dávid, Gyula Tolvaj, Endre Ibrányi, L. Telegdy, A. Pár, László Romics, I. Karádi, M. Horányi, Judit Gervain, Pál Ribiczey, Mihály Csöndes, G. Füst

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Previously we detected more than 3 times higher anti-cholesterol antibody (ACHA) levels in HIV positive patients compared to healthy individuals, however, this level significantly decreased during highly active anti-retroviral therapy (HAART). In our present study we examined whether these findings could also be detected in patients with chronic hepatitis C (CHC). We calculated the correlation between the ACHA levels and the C5b-9 complement activation product. 39 patients with CHC were treated with IFN-α-2b (Schering-Plough) 5 MU daily for 6 weeks, followed by 5 MU TIW. Serum levels of ACHA and complement activation products were measured with ELISA. Serum HCV RNA was measured by a highly sensitive branched DNA technique before and 3,6 and 12 months after the beginning of IFN-α-2b therapy. 52 healthy persons served as controls. At the onset of treatment ACHA level was significantly (p=0.0062) higher in patients (40 (24-69)AU/ml)(median (interquartile range)) than in control sera (26 (20-35) AU/ml). In the 26 responder patients ACHA levels decreased to the normal level during the therapy, but no change was observed in the 13 non-responders. In patients with a sustained response ACHA levels remained low till the end of the 12 months IFN treatment. ACHA levels were significantly (p = 0.0422) higher in the patients with low (

Original languageEnglish
Pages (from-to)161-168
Number of pages8
JournalImmunobiology
Volume207
Issue number3
DOIs
Publication statusPublished - 2003

Fingerprint

Chronic Hepatitis C
Anti-Idiotypic Antibodies
Cholesterol
Serum
Complement Activation
Therapeutics
Complement Membrane Attack Complex
Enzyme-Linked Immunosorbent Assay
HIV
RNA
DNA

ASJC Scopus subject areas

  • Immunology

Cite this

Serum anti-cholesterol antibodies in chronic hepatitis-C patients during IFN-α-2b treatment. / Bíró, Adrienn; Horváth, A.; Varga, L.; Nemesánszky, Elemér; Csepregi, Antal; Dávid, Károly; Tolvaj, Gyula; Ibrányi, Endre; Telegdy, L.; Pár, A.; Romics, László; Karádi, I.; Horányi, M.; Gervain, Judit; Ribiczey, Pál; Csöndes, Mihály; Füst, G.

In: Immunobiology, Vol. 207, No. 3, 2003, p. 161-168.

Research output: Contribution to journalArticle

Bíró, A, Horváth, A, Varga, L, Nemesánszky, E, Csepregi, A, Dávid, K, Tolvaj, G, Ibrányi, E, Telegdy, L, Pár, A, Romics, L, Karádi, I, Horányi, M, Gervain, J, Ribiczey, P, Csöndes, M & Füst, G 2003, 'Serum anti-cholesterol antibodies in chronic hepatitis-C patients during IFN-α-2b treatment', Immunobiology, vol. 207, no. 3, pp. 161-168. https://doi.org/10.1078/0171-2985-00229
Bíró, Adrienn ; Horváth, A. ; Varga, L. ; Nemesánszky, Elemér ; Csepregi, Antal ; Dávid, Károly ; Tolvaj, Gyula ; Ibrányi, Endre ; Telegdy, L. ; Pár, A. ; Romics, László ; Karádi, I. ; Horányi, M. ; Gervain, Judit ; Ribiczey, Pál ; Csöndes, Mihály ; Füst, G. / Serum anti-cholesterol antibodies in chronic hepatitis-C patients during IFN-α-2b treatment. In: Immunobiology. 2003 ; Vol. 207, No. 3. pp. 161-168.
@article{d06cd93881ec4b588cb9cc12b474cc25,
title = "Serum anti-cholesterol antibodies in chronic hepatitis-C patients during IFN-α-2b treatment",
abstract = "Previously we detected more than 3 times higher anti-cholesterol antibody (ACHA) levels in HIV positive patients compared to healthy individuals, however, this level significantly decreased during highly active anti-retroviral therapy (HAART). In our present study we examined whether these findings could also be detected in patients with chronic hepatitis C (CHC). We calculated the correlation between the ACHA levels and the C5b-9 complement activation product. 39 patients with CHC were treated with IFN-α-2b (Schering-Plough) 5 MU daily for 6 weeks, followed by 5 MU TIW. Serum levels of ACHA and complement activation products were measured with ELISA. Serum HCV RNA was measured by a highly sensitive branched DNA technique before and 3,6 and 12 months after the beginning of IFN-α-2b therapy. 52 healthy persons served as controls. At the onset of treatment ACHA level was significantly (p=0.0062) higher in patients (40 (24-69)AU/ml)(median (interquartile range)) than in control sera (26 (20-35) AU/ml). In the 26 responder patients ACHA levels decreased to the normal level during the therapy, but no change was observed in the 13 non-responders. In patients with a sustained response ACHA levels remained low till the end of the 12 months IFN treatment. ACHA levels were significantly (p = 0.0422) higher in the patients with low (",
author = "Adrienn B{\'i}r{\'o} and A. Horv{\'a}th and L. Varga and Elem{\'e}r Nemes{\'a}nszky and Antal Csepregi and K{\'a}roly D{\'a}vid and Gyula Tolvaj and Endre Ibr{\'a}nyi and L. Telegdy and A. P{\'a}r and L{\'a}szl{\'o} Romics and I. Kar{\'a}di and M. Hor{\'a}nyi and Judit Gervain and P{\'a}l Ribiczey and Mih{\'a}ly Cs{\"o}ndes and G. F{\"u}st",
year = "2003",
doi = "10.1078/0171-2985-00229",
language = "English",
volume = "207",
pages = "161--168",
journal = "Immunobiology",
issn = "0171-2985",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "3",

}

TY - JOUR

T1 - Serum anti-cholesterol antibodies in chronic hepatitis-C patients during IFN-α-2b treatment

AU - Bíró, Adrienn

AU - Horváth, A.

AU - Varga, L.

AU - Nemesánszky, Elemér

AU - Csepregi, Antal

AU - Dávid, Károly

AU - Tolvaj, Gyula

AU - Ibrányi, Endre

AU - Telegdy, L.

AU - Pár, A.

AU - Romics, László

AU - Karádi, I.

AU - Horányi, M.

AU - Gervain, Judit

AU - Ribiczey, Pál

AU - Csöndes, Mihály

AU - Füst, G.

PY - 2003

Y1 - 2003

N2 - Previously we detected more than 3 times higher anti-cholesterol antibody (ACHA) levels in HIV positive patients compared to healthy individuals, however, this level significantly decreased during highly active anti-retroviral therapy (HAART). In our present study we examined whether these findings could also be detected in patients with chronic hepatitis C (CHC). We calculated the correlation between the ACHA levels and the C5b-9 complement activation product. 39 patients with CHC were treated with IFN-α-2b (Schering-Plough) 5 MU daily for 6 weeks, followed by 5 MU TIW. Serum levels of ACHA and complement activation products were measured with ELISA. Serum HCV RNA was measured by a highly sensitive branched DNA technique before and 3,6 and 12 months after the beginning of IFN-α-2b therapy. 52 healthy persons served as controls. At the onset of treatment ACHA level was significantly (p=0.0062) higher in patients (40 (24-69)AU/ml)(median (interquartile range)) than in control sera (26 (20-35) AU/ml). In the 26 responder patients ACHA levels decreased to the normal level during the therapy, but no change was observed in the 13 non-responders. In patients with a sustained response ACHA levels remained low till the end of the 12 months IFN treatment. ACHA levels were significantly (p = 0.0422) higher in the patients with low (

AB - Previously we detected more than 3 times higher anti-cholesterol antibody (ACHA) levels in HIV positive patients compared to healthy individuals, however, this level significantly decreased during highly active anti-retroviral therapy (HAART). In our present study we examined whether these findings could also be detected in patients with chronic hepatitis C (CHC). We calculated the correlation between the ACHA levels and the C5b-9 complement activation product. 39 patients with CHC were treated with IFN-α-2b (Schering-Plough) 5 MU daily for 6 weeks, followed by 5 MU TIW. Serum levels of ACHA and complement activation products were measured with ELISA. Serum HCV RNA was measured by a highly sensitive branched DNA technique before and 3,6 and 12 months after the beginning of IFN-α-2b therapy. 52 healthy persons served as controls. At the onset of treatment ACHA level was significantly (p=0.0062) higher in patients (40 (24-69)AU/ml)(median (interquartile range)) than in control sera (26 (20-35) AU/ml). In the 26 responder patients ACHA levels decreased to the normal level during the therapy, but no change was observed in the 13 non-responders. In patients with a sustained response ACHA levels remained low till the end of the 12 months IFN treatment. ACHA levels were significantly (p = 0.0422) higher in the patients with low (

UR - http://www.scopus.com/inward/record.url?scp=0037514556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037514556&partnerID=8YFLogxK

U2 - 10.1078/0171-2985-00229

DO - 10.1078/0171-2985-00229

M3 - Article

C2 - 12777057

AN - SCOPUS:0037514556

VL - 207

SP - 161

EP - 168

JO - Immunobiology

JF - Immunobiology

SN - 0171-2985

IS - 3

ER -